Navigation Links
Kensey Nash Reports Strong Second Quarter and First Six Month Fiscal Year 2009 Results
Date:1/28/2009

r. Total revenues are anticipated to be in the range of $20.4 to $21.1 million.

The Company expects fiscal 2009 third quarter diluted earnings per share of $0.40 to $0.42 per share, representing an increase of 43% to 50% compared to diluted earnings per share of $0.28 for the same period of fiscal year 2008. The Company expects this significant improvement from the prior fiscal year primarily due to anticipated increases in biomaterial sales and royalties, coupled with the elimination of the endovascular sales and marketing expenses, partially offset by an anticipated increase in biomaterials research and development expenses.

Updated Guidance for Fiscal Year Ending June 30, 2009 (Fiscal 2009)

The Company is reaffirming its previous guidance estimate for diluted earnings per share in a range of $1.62 to $1.69 for fiscal 2009. Net sales are currently estimated to be in a range of $55.0 to $55.5 million, representing a 2% to 3% increase from the prior fiscal year. Biomaterial sales are expected to be in the range of $51.0 million to $51.4 million, representing an increase of 7% to 8% from the comparable prior fiscal year quarter, and endovascular sales are expected to be approximately $4.0 million, representing a decrease of 36% from the prior fiscal year. Royalties are currently estimated to be in a range of $27.0 to $28.0 million, representing a 4% to 8% increase from the prior fiscal year. Royalty guidance has been lowered by approximately $1.0 million due to the negative effects of changes in foreign currency exchange rates. The Company's previous guidance estimated that the U.S. Dollar to Euro exchange rate would average 1.44, but the Company has revised its estimate to approximately 1.33 for the remainder of fiscal 2009 based on current market conditions. Despite decreases in revenue expectations from the Company's previous guidance, the Company's diluted earnings per share guidance remains unchan
'/>"/>

SOURCE Kensey Nash Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Kensey Nash Reports Fourth Quarter and Fiscal Year 2008 Results
2. Kensey Nash Corporation Announces Its Third Quarter 2008 Earnings Release Date and Teleconference
3. Kensey Nash Receives FDA 510(k) Clearance for New Safe-Cross(R) Vessel Wall Detection Technology
4. Kensey Nash to Present at the Canaccord Adams Small-Cap Orthopedics Conference
5. Kensey Nash to Participate in the Sidoti Fifth Annual Palm Beach Emerging Growth Institutional Investor Forum Conference
6. Kensey Nash to Participate in the RBC Capital Markets Healthcare Conference
7. Kensey Nash to Present at the Sidoti Sixth Annual West Coast Emerging Growth Institutional Investor Forum Conference
8. Aerolase Reports Strong Sales in 2008 for Portable Aesthetic Lasers
9. GEN Reports on Growing Reliance on Microfluidics Technology
10. Novozymes Reports Strong 2008 Results
11. International Robotic Urology Symposium Reports on Benefits of Cooling During Robotic-Assisted Prostate Surgery and Introduces InnerCools New Investigational UroCool System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... IDIX ) announced today that it will report,its ... Tuesday, November 6,2007 after the U.S. financial markets close. ... release, Idenix,management will host a conference call at 4:30 ... company,s financial results for the third quarter,2007. To ...
... 31 Modigene Inc. (OTC,Bulletin Board: MODG) today announced ... & Renshaw 9th Annual Healthcare Conference on,Wednesday, November 7, ... held at,the New York Palace Hotel in New York ... Novik will attend.,Management will provide a company overview and ...
... DIEGO, Oct. 31 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... Acumen,BioFin(TM) Rodman & Renshaw 9th Annual Healthcare Conference on ... PST). The conference is being,held at the New York ... Executive Officer of Anadys,Pharmaceuticals, Inc. will present an overview ...
Cached Biology Technology:Modigene to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference 2Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference 2
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... , Dec. 2, 2014 As part ... readers, Inception Technologies is pleased to announce the release ... for customers to collect the workforce data that they ... that have been left by existing readers. Many such ... interface, connectivity and modern technology. Older models force users ...
Breaking Biology News(10 mins):Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2
... scientific institutions today announced the launch of the Encyclopedia ... 1.8 million named species of animals, plants, and other ... time in the history of the planet, scientists, students, ... living species, even those that have just been discovered. ...
... that could revolutionize manufacturing for certain materials, researchers have ... world. While still slightly less than 2 centimeters long, ... , The fibers--which have the potential to be longer, ... many other materials--could ultimately find use in smart fabrics, ...
... study examines the use of tissue-engineered scaffolding made of ... naturally, to replace defective cartilage tissue. Cartilage cells are ... into the body, where new cartilage tissue is grown ... Artificial Organs. , The procedure was extremely successful in ...
Cached Biology News:World's leading scientists announce creation of 'Encyclopedia of Life' 2World's leading scientists announce creation of 'Encyclopedia of Life' 3World's leading scientists announce creation of 'Encyclopedia of Life' 4The longest carbon nanotubes you've ever seen 2
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... cassette is designed to allow ampicillin ... promoter gb2 driving the gene for ampicillin ... the Em7 promoter. It mediates higher transcription ... A synthetic polyadenylation signal terminates the ampicillin ...
... is designed for the fast and simple ... at any position (for the generation of ... is designed to allow neomycin / kanamycin ... combines a prokaryotic promoter (gb2) for expression ...
... Pyronin Y is most widely used ... selectively and differentially stain nucleic acids ... dichromatic dye solution, Pyronin Y stains ... DNA green. Chem comp: ...
Biology Products: